FcγR interaction is not required for effective anti‐PD‐L1 immunotherapy but can add additional benefit depending on the tumor model
2019
Immunomodulatory antibodies blocking interactions of coinhibitory receptors to their ligands such as
CTLA-4, PD1 and
PD-L1on immune cells have shown impressive therapeutic efficacy in clinical studies. The therapeutic effect of these antibodies is mainly mediated by reactivating antitumor T cell immune responses. Detailed analysis of anti-CTLA4
antibody therapyrevealed that an optimal therapeutic efficacy also requires binding to
Fc receptorsfor IgG, FcγR, mediating depletion of intratumoral regulatory T cells. Here, we investigated the role of Fc binding in anti-
PD-L1
antibody therapyin the MC38
C57BL/6and CT26 BALB/c colon adenocarcinoma tumor models. In the MC38 tumor model, all IgG
subclassesanti-
PD-L1showed similar therapeutic efficacy when compared to each other in either wild-type mice or in mice deficient for all FcγR. In contrast, in the CT26 tumor model, anti-
PD-L1mIgG2a, the IgG
subclasswith the highest affinity for activating FcγR, showed stronger therapeutic efficacy than other IgG
subclasses. This was associated with a reduction of a myeloid cell subset with high expression of
PD-L1in the tumor microenvironment. This
subclasspreference for mIgG2a was lost in
C57BL/6× BALB/c F1 mice, indicating that the genetic background of the host may determine the additional clinical benefit of the high affinity antibody
subclasses. Based on these data, we conclude that FcγR are not crucial for anti-
PD-L1
antibody therapybut might play a role in some tumor models.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
42
References
8
Citations
NaN
KQI